Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovista has entered into a pilot research collaboration agreement with Pfizer to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista's Clinical Outcome Search Space (COSS) technology.
Subscribe to our email newsletter
As per the terms of the agreement, Biovista will collaborate with Pfizer’s Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates.
Pfizer Indications Discovery Unit chief scientific officer Don Frail said that they seek to benefit from the collaboration with Biovista and their COSS technology to expand uses for our drugs and to help accelerate our clinical programs.
Biovista president Aris Persidis said that working with Pfizer on potential new indications may benefit expanded sets of patients with unmet medical needs, and is an opportunity to demonstrate the value of Biovista’s COSS technology within the drug development workflow of bio-pharmaceutical companies.